Delivery Order SPE2DB25D3306-SPE2DB25FUBTS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,351.08 to AmerisourceBergen Drug Corp for WIXELA 250-50 inhaler units (60-count) on April 25, 2025, with an ultimate completion date of April 28, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $2,155.90 to AmerisourceBergen Drug Corp for WIXELA 250-50 inhalers (60-count units) on September 19, 2025, with completion scheduled for September 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award to the prime contractor at its Conshohocken, Pennsylvania location. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,564.83 delivery order to AmerisourceBergen Drug Corp for WIXELA 500-50 inhaler products on June 2, 2025, with an ultimate completion date of June 3, 2025. This contract was issued under firm fixed pricing with no set-aside designation, indicating competitive award conditions. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. As a child delivery order, this award is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,378.26 to AmerisourceBergen Drug Corp for WIXELA 500-50 inhalers (60-count) on September 2, 2025, with ultimate completion by September 3, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a small-value transaction typical of routine pharmaceutical supply replenishment orders. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work from its...
- The Defense Logistics Agency awarded a delivery order valued at $1,378.26 to AmerisourceBergen Drug Corp for WIXELA 500-50 inhaler units (60-count) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. The award was made without a set-aside designation, and performance will take place at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $2,374.92 to AmerisourceBergen Drug Corp for WIXELA 250-50 inhalers (60-count), with an ultimate completion date of August 29, 2025. This non-set-aside, firm fixed price delivery order was competitively awarded and represents a direct fulfillment of pharmaceutical supply needs through AmerisourceBergen's existing contract vehicle. The product will be delivered to the vendor's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for WIXELA 250-50 inhalation powder (60-unit package) with a ceiling value of $1,733.01. This is a firm fixed-price delivery order with an ultimate completion date of August 25, 2025, and represents a non-set-aside competitive award. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,650.57 to AmerisourceBergen Drug Corp for Wixela 500-50 inhaler, 60-count units. This is a firm fixed-price, non-set-aside contract awarded on August 6, 2025, with an ultimate completion date of August 7, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for WIXELA 100-50 inhalers in a 60-count configuration. This $1,430.16 firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The award was made without a set-aside designation, reflecting competitive...
- The Defense Logistics Agency awarded a delivery order valued at $4,501.44 to AmerisourceBergen Drug Corp for WIXELA 250-50 INHUB 60S on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. WIXELA is a combination inhalation medication used to treat chronic obstructive pulmonary disease and...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUBTSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,030.31 to AmerisourceBergen Drug Corp for WIXELA 250-50 inhaler units (60-count). The contract, which became effective on May 20, 2025, with completion by May 21, 2025, is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at approximately $1 billion through December 2026, which serves as the primary pharmaceutical supply vehicle for federal military and healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing comprehensive medical supplies to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's contract portfolio with DLA demonstrates its critical role in supplying brand-name and generic pharmaceuticals, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This WIXELA delivery order represents a routine fulfillment under the established IDC vehicle, supporting respiratory care requirements within the federal military healthcare supply chain. WIXELA is a combination inhaled corticosteroid and long-acting beta-agonist used for asthma and chronic obstructive pulmonary disease management in military beneficiaries and personnel.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 5/20/25 |